Coronary Microvascular DiseaseNCT05369182
Multicenter Registry of Coronary Flow-Derived Indexes for Coronary Microvascular Disease (Multicenter FLOW-CMD Registry)
An observational study of Coronary Microvascular Disease and Coronary Artery Disease, run by Samsung Medical Center at 7 sites in South Korea.
Trial summary
Multicenter FLOW-CMD registry is a prospective, multi-center, registry study. The aim of the study is to evaluate prognostic implications of coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) undergoing revascularization decision using FFR or other non-hyperemic pressure ratios. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease
- What is being tested?
- Invasive physiologic assessment and Intravascular imaging
- How many people
- 1,003 participants
- Where
- 7 sitesSouth Korea
- Study dates
- 22 Apr 2022to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with suspected IHD undergoing invasive coronary angiography and clinically indicated physiological assessment will be eligible. A total of 1,003 patients will be enrolled at 7 centers in South Korea.
Who may be able to join
- Subject must be ≥18 years
- Patients suspected with IHD
- Patients undergoing physiologic assessment (CFR, IMR, and FFR) for evaluation of severity of CAD
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written informed consent to any study related procedure.
Who cannot join
- Cardiogenic shock (systolic blood pressure <90mmHg or requiring inotropics to maintain blood pressure >90mmHg) or cardiac arrest
- Non-cardiac co-morbid conditions are present with life expectancy <2 year (per site investigator's medical judgment).
- Inability to undergo physiologic assessment (CFR, IMR, and FFR)
- Pregnant or lactating women
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
South Korea7 sites
Chonnam National University Hospital
Gwangju
Chosun University Hospital
Gwangju
Gyeongsang National University Hospital
Jinju
Seoul National University Bundang Hospital
Seongnam
Samsung Medical Center
Seoul
Seoul National University Boramae Medical Center
Seoul
Seoul St. Mary's Hospital
Seoul
About this study
Official title: Prospective Registry of Coronary Flow-Derived Indexes in Patients With Coronary Artery Disease
Multicenter FLOW-CMD registry is a prospective, multi-center, registry study.
The aim of the study is to evaluate prognostic implications of coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) undergoing revascularization decision using FFR or other non-hyperemic pressure ratios.
Read the detailed description
The diagnostic and therapeutic strategies in patients with coronary artery disease (CAD) have focused on identifying and alleviating both extent and severity of myocardial ischemia, as it is the most important prognostic fator. Thus, fractional flow reserve (FFR) has been a standard method for identifying ischemia-related epicardial coronary stenosis, accruing an abundance of clinical evidence on the benefit of FFR-guided treatment decisions. However, a high FFR value (>0.80) does not necessarily imply freedom from future events. Indeed, clinical events still occur in patients who are deferred based on high FFR. The microvasculature is one of the main components of coronary circulatory system, and the presence of microvascular disease may contribute to clinical events in patients without epicardial coronary stenosis. In the cardiac catheterization laboratory, microvascular disease can be assessed using a pressure/temperature-sensor coronary wire or a Doppler wire. Previous studies have demonstrated the incremental prognostic implications of coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) in patients with high FFR, and the recent European guidelines supported the importance of invasive physiologic assessment using CFR and IMR in patients with stable coronary artery disease. Furthermore, recent Expert Consensus Documents and the European Society of Cardiology guideline of Chronic Coronary Syndrome have underlined the importance of evaluating coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) and proposed an universal definition of CMD based on: 1) functionally non-obstructive CAD defined by a fractional flow reserve (FFR)>0.80 and 2) impaired coronary microvascular function determined by abnormal CFR and/or microvascular resistance.
Another important issue in contemporary practice is how to improve patient prognosis after percutaneous coronary intervention (PCI). Although PCI can induce secondary CMD originated from multiple mechanism associated with the procedure (e.g. distal embolization or endothelial dysfunction), and although secondary CMD also affects coronary circulatory function, there has been no previous evidence evaluating the incidence and prognosis of secondary CMD after successful PCI for epicardial coronary stenosis. Furthermore, both previous and recent trials demonstrated that intravascular imaging-guided PCI optimization has significantly better clinical outcomes than angiography-only guided PCI. However, these trials could not explain the exact mechanism underlying the potential benefit of intravascular imaging-guided PCI optimization for better clinical outcome, aside from a larger final stent area following intravascular imaging-guided PCI. Although the fundamental purpose of PCI is to resolve inducible myocardial ischemia originated from epicardial coronary stenosis, several studies have demonstrated that a substantial proportion of patients who underwent angiographically successful PCI had suboptimal post-PCI FFR or non-hyperemic pressure ratios, which are independently associated with worse clinical outcomes. Previous studies demonstrated that intravascular imaging devices could identify correctable cause of suboptimal post-PCI FFR. In this regard, it can be expected that intravascular imaging-guided PCI optimization would result in better post-PCI physiologic results such as higher post-PCI FFR and CFR, compared with angiography-only guided PCI.
However, these issues have not been fully clarified. Regarding the prognostic impact of CMD, only limited data has been available on the prognostic implications of CMD defined by the universal definition among patients with IHD, especially in patients with insignificant epicardial coronary disease defined by FFR>0.80. In addition, only one prospective study evaluated optical coherence tomography (OCT)-guided PCI for post-PCI FFR in patients with non-ST segment elevation myocardial infarction. None of prospective study evaluated potential physiologic benefit of intravascular imaging-guided PCI optimization using intravascular ultrasound (IVUS) or OCT in unselected patient population.
Therefore, the primary objectives of the current multicenter prospective registry are to evaluate prognostic implications of CMD in patients with suspected IHD undergoing revascularization decision using FFR or other non-hyperemic pressure ratios and to evaluate the efficacy of intravascular imaging-guided optimization to enhance post-revascularization coronary circulatory function, compared with angiography-only guided revascularization in revascularized population.
- Being tested
- Invasive physiologic assessment, Intravascular imaging
- Keywords
- Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease, Coronary Flow Reserve, Index of Microcirculatory Resistance, Fractional Flow Reserve, Intravascular Ultrasound, Optical Coherence Tomography
- Medical subject headings
- Microvascular Angina, Coronary Artery Disease, Myocardial Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Invasive physiologic assessmentDiagnostic test
All coronary physiologic parameters are measured following diagnostic angiography. Resting pd/pa, FFR, CFR and IMR will be calculated using coronary physiologic parameters.
In patients treated by PCI, post-PCI physiologic assessment including CFR, IMR, and FFR will be performed.
Intravascular imagingDiagnostic test
By the operator's discretion, stent-optimization will be performed under intravascular imaging devices (IVUS [Boston Scientific, Natick, Massachusetts, USA] or OCT [Abbott Vascular], St. Paul, MN, USA]).
| Study group | Role | What they receive |
|---|---|---|
| Total Population: Patients with CMD (CFR<2.0 and IMR≥25) | Among the enrolled patients, those who are diagnosed with CMD (CFR<2.0, IMR≥25) in physiologic assessment. Receives: Diagnostic Test: Invasive physiologic assessment | |
| Total Population: Patients with preserved microvascular function (CFR≥2.0 OR IMR<25) | Among the enrolled patients, those who are with preserved microvascular function (CFR≥2.0 OR IMR<25) in physiologic assessment. Receives: Diagnostic Test: Invasive physiologic assessment | |
| Revascularized Population: Patients treated by intravascular imaging-guided PCI optimization | Among patients who received PCI, patients whose PCI was optimized through intravascular imaging device (IVUS or OCT). Receives: Diagnostic Test: Invasive physiologic assessment; Diagnostic Test: Intravascular imaging | |
| Revascularized Population: Patients treated by angiography-only guided PCI | Among patients who received PCI, patients whose PCI was optimized through angiography-only. Receives: Diagnostic Test: Invasive physiologic assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient-oriented composite outcomes (POCO)
a composite of all-cause death, MI, any repeat revascularization, or admission for heart failure
Measured: 1 year after last patient enrollment
Secondary outcomes (13)
All-cause death
All-cause death
Measured: 1 year after last patient enrollment
Cardiac death
Cardiac death
Measured: 1 year after last patient enrollment
Target-vessel MI
Target-vessel MI
Measured: 1 year after last patient enrollment
Non-target vessel MI
Non-target vessel MI
Measured: 1 year after last patient enrollment
Any MI
Any MI
Measured: 1 year after last patient enrollment
Target vessel revascularization (clinically-driven or all)
Target vessel revascularization (clinically-driven or all)
Measured: 1 year after last patient enrollment
Non-target vessel revascularization (clinically-driven or all)
Non-target vessel revascularization (clinically-driven or all)
Measured: 1 year after last patient enrollment
Any repeat revascularization (clinically-driven or all)
Any repeat revascularization (clinically-driven or all)
Measured: 1 year after last patient enrollment
Admission for congestive heart failure
Admission for congestive heart failure
Measured: 1 year after last patient enrollment
Stroke (ischemic and hemorrhagic)
Stroke (ischemic and hemorrhagic)
Measured: 1 year after last patient enrollment
Seattle Angina Questionnaire
Physical limitation, Angina stability, Angina frequency, Treatment satisfaction, Quality of life
Measured: Baseline, 1 year, and 2 year after patient enrollment
Proportion of functionally optimized post-PCI results
Proportion of functionally optimized post-PCI results (Post-PCI FFR>0.80 and CFR>2.0) according to the use of intravascular imaging
Measured: Post-procedure
Incidence of secondary CMD after PCI
Incidence of secondary CMD (CFR<2.0 and IMR≥25) after PCI among revascularized population
Measured: Post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2022
- Study start22 Apr 2022
- Primary completion31 Dec 2025
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Coronary Microvascular DiseaseStudies of the same condition, open and under way.
- More trials run by Samsung Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,003 participants (actual)
Sponsor and investigators
- Lead sponsor
- Samsung Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Chonnam National University Hospital, Chosun University Hospital, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital
- Responsible party
- Principal investigator, Joo Myung Lee, Samsung Medical Center
- Investigators
- Joo Myung Lee, MD, MPH, PhD, Principal investigator, Samsung Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05369182
- Sponsor's protocol ID
- MulticenterFLOW
- Status last verified
- Feb 2026
- First submitted
- 23 Apr 2022
- Last updated
- 12 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
Publications
Lee SH, Ahn JH, Jones WS, Park S, Lim Y, Oh S, Hyun DY, Cho KH, Kim MC, Sim DS, Gim DH, Lee SY, Choi KH, Kim HK, Lee KY, Choo EH, Jeon KH, Kim H, Kang MG, Koh JS, Joh HS, Park TK, Yang JH, Song YB, Choi SH, Gwon HC, Hahn JY, Kim JH, Ahn Y, Lee JM, Hong YJ; Multicenter FLOW-CMD investigators. Microvascular resistance reserve and cardiovascular outcomes: the FLOW-CMD registry. Eur Heart J. 2026 Aug 28:ehag705. doi: 10.1093/eurheartj/ehag705. Online ahead of print.
PubMed 42661450Lee JM, Lee SH, Gim DH, Lee SY, Choi KH, Ahn JH, Hong YJ, Kim HK, Lee KY, Choo EH, Jeon KH, Kim H, Kang MG, Koh JS, Joh HS, Park TK, Yang JH, Song YB, Choi SH, Gwon HC, Hahn JY; Multicenter FLOW-CMD investigators. Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea. Lancet. 2026 Jun 6;407(10545):2319-2328. doi: 10.1016/S0140-6736(26)00666-5. Epub 2026 May 21.
PubMed 42167298
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Registry of Coronary Flow-Derived Indexes in Patients With Coronary Artery Disease
- ClinicalTrials.gov ID
- NCT05369182
- Acronym / sponsor ID
- MulticenterFLOW
- Keywords
- Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease, Coronary Flow Reserve, Index of Microcirculatory Resistance, Fractional Flow Reserve, Intravascular Ultrasound, Optical Coherence Tomography
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,003 participants (actual)
- Lead sponsor
- Samsung Medical CenterUniversity, hospital or other
- Collaborators
- Chonnam National University Hospital, Chosun University Hospital, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital
- Study start
- 22 Apr 2022 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 11 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multicenter FLOW-CMD registry is a prospective, multi-center, registry study.
The aim of the study is to evaluate prognostic implications of coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) undergoing revascularization decision using FFR or other non-hyperemic pressure ratios.
Detailed description
The diagnostic and therapeutic strategies in patients with coronary artery disease (CAD) have focused on identifying and alleviating both extent and severity of myocardial ischemia, as it is the most important prognostic fator. Thus, fractional flow reserve (FFR) has been a standard method for identifying ischemia-related epicardial coronary stenosis, accruing an abundance of clinical evidence on the benefit of FFR-guided treatment decisions. However, a high FFR value (>0.80) does not necessarily imply freedom from future events. Indeed, clinical events still occur in patients who are deferred based on high FFR. The microvasculature is one of the main components of coronary circulatory system, and the presence of microvascular disease may contribute to clinical events in patients without epicardial coronary stenosis. In the cardiac catheterization laboratory, microvascular disease can be assessed using a pressure/temperature-sensor coronary wire or a Doppler wire. Previous studies have demonstrated the incremental prognostic implications of coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) in patients with high FFR, and the recent European guidelines supported the importance of invasive physiologic assessment using CFR and IMR in patients with stable coronary artery disease. Furthermore, recent Expert Consensus Documents and the European Society of Cardiology guideline of Chronic Coronary Syndrome have underlined the importance of evaluating coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) and proposed an universal definition of CMD based on: 1) functionally non-obstructive CAD defined by a fractional flow reserve (FFR)>0.80 and 2) impaired coronary microvascular function determined by abnormal CFR and/or microvascular resistance.
Another important issue in contemporary practice is how to improve patient prognosis after percutaneous coronary intervention (PCI). Although PCI can induce secondary CMD originated from multiple mechanism associated with the procedure (e.g. distal embolization or endothelial dysfunction), and although secondary CMD also affects coronary circulatory function, there has been no previous evidence evaluating the incidence and prognosis of secondary CMD after successful PCI for epicardial coronary stenosis. Furthermore, both previous and recent trials demonstrated that intravascular imaging-guided PCI optimization has significantly better clinical outcomes than angiography-only guided PCI. However, these trials could not explain the exact mechanism underlying the potential benefit of intravascular imaging-guided PCI optimization for better clinical outcome, aside from a larger final stent area following intravascular imaging-guided PCI. Although the fundamental purpose of PCI is to resolve inducible myocardial ischemia originated from epicardial coronary stenosis, several studies have demonstrated that a substantial proportion of patients who underwent angiographically successful PCI had suboptimal post-PCI FFR or non-hyperemic pressure ratios, which are independently associated with worse clinical outcomes. Previous studies demonstrated that intravascular imaging devices could identify correctable cause of suboptimal post-PCI FFR. In this regard, it can be expected that intravascular imaging-guided PCI optimization would result in better post-PCI physiologic results such as higher post-PCI FFR and CFR, compared with angiography-only guided PCI.
However, these issues have not been fully clarified. Regarding the prognostic impact of CMD, only limited data has been available on the prognostic implications of CMD defined by the universal definition among patients with IHD, especially in patients with insignificant epicardial coronary disease defined by FFR>0.80. In addition, only one prospective study evaluated optical coherence tomography (OCT)-guided PCI for post-PCI FFR in patients with non-ST segment elevation myocardial infarction. None of prospective study evaluated potential physiologic benefit of intravascular imaging-guided PCI optimization using intravascular ultrasound (IVUS) or OCT in unselected patient population.
Therefore, the primary objectives of the current multicenter prospective registry are to evaluate prognostic implications of CMD in patients with suspected IHD undergoing revascularization decision using FFR or other non-hyperemic pressure ratios and to evaluate the efficacy of intravascular imaging-guided optimization to enhance post-revascularization coronary circulatory function, compared with angiography-only guided revascularization in revascularized population.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Total Population: Patients with CMD (CFR<2.0 and IMR≥25) | – | Diagnostic Test: Invasive physiologic assessmentAmong the enrolled patients, those who are diagnosed with CMD (CFR<2.0, IMR≥25) in physiologic assessment. |
| Total Population: Patients with preserved microvascular function (CFR≥2.0 OR IMR<25) | – | Diagnostic Test: Invasive physiologic assessmentAmong the enrolled patients, those who are with preserved microvascular function (CFR≥2.0 OR IMR<25) in physiologic assessment. |
| Revascularized Population: Patients treated by intravascular imaging-guided PCI optimization | – | Diagnostic Test: Invasive physiologic assessment, Diagnostic Test: Intravascular imagingAmong patients who received PCI, patients whose PCI was optimized through intravascular imaging device (IVUS or OCT). |
| Revascularized Population: Patients treated by angiography-only guided PCI | – | Diagnostic Test: Invasive physiologic assessmentAmong patients who received PCI, patients whose PCI was optimized through angiography-only. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with suspected IHD undergoing invasive coronary angiography and clinically indicated physiological assessment will be eligible. A total of 1,003 patients will be enrolled at 7 centers in South Korea.
Key inclusion criteria (4 listed)
- Subject must be ≥18 years
- Patients suspected with IHD
- Patients undergoing physiologic assessment (CFR, IMR, and FFR) for evaluation of severity of CAD
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written informed consent to any study related procedure.
Key exclusion criteria (4 listed)
- Cardiogenic shock (systolic blood pressure <90mmHg or requiring inotropics to maintain blood pressure >90mmHg) or cardiac arrest
- Non-cardiac co-morbid conditions are present with life expectancy <2 year (per site investigator's medical judgment).
- Inability to undergo physiologic assessment (CFR, IMR, and FFR)
- Pregnant or lactating women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Invasive physiologic assessmentAll coronary physiologic parameters are measured following diagnostic angiography. Resting pd/pa, FFR, CFR and IMR will be calculated using coronary physiologic parameters. In patients treated by PCI, post-PCI physiologic assessment including CFR, IMR, and FFR will be performed. | Diagnostic test | Revascularized Population: Patients treated by angiography-only guided PCI, Revascularized Population: Patients treated by intravascular imaging-guided PCI optimization, Total Population: Patients with CMD (CFR<2.0 and IMR≥25), Total Population: Patients with preserved microvascular function (CFR≥2.0 OR IMR<25) |
| Intravascular imagingBy the operator's discretion, stent-optimization will be performed under intravascular imaging devices (IVUS [Boston Scientific, Natick, Massachusetts, USA] or OCT [Abbott Vascular], St. Paul, MN, USA]). | Diagnostic test | Revascularized Population: Patients treated by intravascular imaging-guided PCI optimization |
Primary outcome
Patient-oriented composite outcomes (POCO)
Time frame: 1 year after last patient enrollment
a composite of all-cause death, MI, any repeat revascularization, or admission for heart failure
13 secondary outcomes
All-cause death
Time frame: 1 year after last patient enrollment
Cardiac death
Time frame: 1 year after last patient enrollment
Target-vessel MI
Time frame: 1 year after last patient enrollment
Non-target vessel MI
Time frame: 1 year after last patient enrollment
Any MI
Time frame: 1 year after last patient enrollment
Target vessel revascularization (clinically-driven or all)
Time frame: 1 year after last patient enrollment
Non-target vessel revascularization (clinically-driven or all)
Time frame: 1 year after last patient enrollment
Any repeat revascularization (clinically-driven or all)
Time frame: 1 year after last patient enrollment
Admission for congestive heart failure
Time frame: 1 year after last patient enrollment
Stroke (ischemic and hemorrhagic)
Time frame: 1 year after last patient enrollment
Seattle Angina Questionnaire
Time frame: Baseline, 1 year, and 2 year after patient enrollment
Proportion of functionally optimized post-PCI results
Time frame: Post-procedure
Incidence of secondary CMD after PCI
Time frame: Post-procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2026.
- Derived from this study: PubMed 42661450Lee SH, Ahn JH, Jones WS, Park S, Lim Y, Oh S, Hyun DY, Cho KH, Kim MC, Sim DS, Gim DH, Lee SY, Choi KH, Kim HK, Lee KY, Choo EH, Jeon KH, Kim H, Kang MG, Koh JS, Joh HS, Park TK, Yang JH, Song YB, Choi SH, Gwon HC, Hahn JY, Kim JH, Ahn Y, Lee JM, Hong YJ; Multicenter FLOW-CMD investigators. Microvascular resistance reserve and cardiovascular outcomes: the FLOW-CMD registry. Eur Heart J. 2026 Aug 28:ehag705. doi: 10.1093/eurheartj/ehag705. Online ahead of print.
- Derived from this study: PubMed 42167298Lee JM, Lee SH, Gim DH, Lee SY, Choi KH, Ahn JH, Hong YJ, Kim HK, Lee KY, Choo EH, Jeon KH, Kim H, Kang MG, Koh JS, Joh HS, Park TK, Yang JH, Song YB, Choi SH, Gwon HC, Hahn JY; Multicenter FLOW-CMD investigators. Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea. Lancet. 2026 Jun 6;407(10545):2319-2328. doi: 10.1016/S0140-6736(26)00666-5. Epub 2026 May 21.
- Individual participant dataSharing planned: Yes. After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
Related trials for Coronary Microvascular Disease
Active, not recruiting
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
Coronary Microvascular Disease, Ischemic Heart Disease
Active, not recruitingObservational study
The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome
Tako Tsubo Cardiomyopathy, Microvascular Dysfunction
Recruiting
Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in Women
ANOCA - Angina With Non-obstructive Coronary Arteries, Coronary Microvascular Dysfunction (CMD)
RecruitingObservational study
Mechanical Dyssynchrony and Microvascular Dysfunction by SPECT
Myocardial Blood Flow Reserve, Mechanical Dyssynchrony
Enrolling by invitationObservational study
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joo Myung Lee, MD, MPH, PhD principal investigator
Samsung Medical Center
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Microvascular Disease and Coronary Artery Disease, run by Samsung Medical Center at 7 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 12 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient-oriented composite outcomes (POCO) (time frame: 1 year after last patient enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05369182, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2026; AzTrials last refreshed its copy on 7 Nov 2026.